Foresite Capital Portfolio
13F Holdings & Position Changes — Last filed Feb 17, 2026
13F Holdings & Position Changes — Last filed Feb 17, 2026
Foresite Capital is a $4B biotech-focused hedge fund managed by Jim Tananbaum, MD. As of their latest 13F filing (Q4 2025), the fund holds 7 positions worth $229.7M. This quarter they initiated 7 new positions and exited 3. Their largest holding is PHVS ($132.6M).
Foresite initiated 7 new positions this quarter. Portfolio grew +766.0% to $229.7M. 24 upcoming catalysts across holdings.
No credit card required
Foresite Capital holds 7 biotech stocks in their 13F portfolio. Their top positions include PHVS, CYTK, LYEL, MAZE, RLAY. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
Foresite Capital's tracked biotech portfolio is worth $229.7M across 7 positions, with total assets under management of approximately $4B. Portfolio values are based on 13F filings with the SEC.
Foresite Capital initiated 7 new positions this quarter, including PHVS, CYTK, LYEL, MAZE, RLAY and 2 more. They also increased 0 existing positions.
Foresite Capital fully exited 3 positions this quarter, including ASND, NTRA, CBAY. They also trimmed 0 existing positions.
Data science-driven healthcare crossover fund investing from late-stage private through public equity. Uses proprietary data analytics and clinical expertise to identify asymmetric risk/reward opportunities across biotech and life sciences.
| 3 |
| LYEL |
| New |
| 800,399 |
| $24.6M |
| 4 | MAZE | New | 522,657 | $21.7M |
| 5 | RLAY | New | 1,000,000 | $8.5M |
| 6 | XENE | New | 160,000 | $7.2M |
| 7 | ALEC | New | 3,887,200 | $6.1M |